Table 1.

Genetic status in canonical driver genes, overall incidence, and prognosis of each pancreatic cancer variants.

Subtype	KRAS	TP53	SMAD4	CDKN2A	Incidence	Prognosis	Ref
CC	30–50%	20%	n.a.	n.a.	1–3%	Good (5-year survival >55%)	[9,10,11,12]
Medullary carcinoma	17–30%	18%	n.a.	n.a.	<1%	Still unclear	[13,14,15,16]
ASC	90–100%	50–90%	18->90%	6%	1–4%	Poor (9 months from the diagnosis)	[17,18,19,20,21,22,23]
UDC	30–70%	30–60%	n.a.	n.a.	<1%	Extremely poor (5 months from the diagnosis	[24,25,26,27,28,29]
UCOGC	70–100%	50–100%	10–50%	25%	<1%	Better than UDC	[24,25,26,27,30,31,32,33,34,35,36]
Rhabdoid carcinoma	40%	40–50%	n.a.	n.a.	<1%	Still unclear	[37]
Hepatoid carcinoma	n.a.	n.a.	n.a.	n.a.	<1%	Still unclear	[38,39]
SRCC	n.a.	n.a.	n.a.	n.a.	<1%	Poor	[40,41]

ASC, adenosquamous carcinoma; CC, colloid carcinoma; n.a., not assessed; SRCC, signet-ring cell carcinoma; UCOGC, undifferentiated carcinoma with osteoclast-like giant cells; UDC, undifferentiated carcinoma.